SCHEMBL8207095

SCHEMBL8207095

CCOC(=O)c1ccc(N2CCC(CO)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.52
HPGD P15428 2/20 0.52
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HSP90AA1 P07900 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
FDFT1 P37268 1/20 0.49
TSHR P16473 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
ESR1 P03372 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
ESR2 Q92731 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1994967 0.92 HTT (0.50) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL24754432 0.89 HTT (0.50) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL5208784 0.88 HTT (0.51) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL24724875 0.87 TSHR (0.52) HPGDALDH1A1KMT2ATSHRESR1
Hydrochloric Acid SCHEMBL6139722 0.86 HTT (0.50) HTTHPGDALDH1A1MEN1KMT2A
Alcohol SCHEMBL27802949 0.86 MEN1 (0.53) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL3457437 0.86 HPGD (0.55) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL7138273 0.86 ALDH1A1 (0.58) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL378276 0.86 TDP1 (0.60) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL20188098 0.85 HPGD (0.65) HTTHPGDALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-11-27 US disclosed
US-12441708-B2 Cereblon ligands and bifunctional compounds comprising the same ARVINAS OPERATIONS, INC. (US) 2025-10-14 US disclosed
US-20250313547-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-10-09 US disclosed
US-12239711-B2 Cereblon ligands and bifunctional compounds comprising the same ARVINAS OPERATIONS, INC. (US) 2025-03-04 US disclosed
CN-112262134-B Cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-05-24 CN disclosed
CN-110612294-B Human cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-01-16 CN disclosed
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 US disclosed
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 US disclosed
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 US disclosed
CN-115974840-A Human cereblon ligand and bifunctional compound comprising same 阿尔维纳斯运营股份有限公司 2023-04-18 CN disclosed
WO-2018144649-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME Arvinas, Inc. (US) 2018-08-09 WO disclosed
WO-2018144649-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME Arvinas, Inc. (US) 2018-08-09 WO disclosed
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2018-08-02 US disclosed
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2018-08-02 US disclosed
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2018-08-02 US disclosed
US-8962825-B2 Hydroxamates as inhibitors of histone deacetylase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-02-24 US disclosed
US-8962825-B2 Hydroxamates as inhibitors of histone deacetylase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-02-24 US disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
WO-2008053131-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 HTT 1235/4885HPGD 4345/4885ALDH1A1 3671/4885
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 HTT 1235/4885HPGD 4345/4885ALDH1A1 3671/4885
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE H1-2, HDAC1, H1-0 HTT 1796/4885HPGD 239/4885ALDH1A1 724/4885
US-12239711-B2 Cereblon ligands and bifunctional compounds comprising the same CRBN, CBL, MDM2 HTT 1235/4885HPGD 4345/4885ALDH1A1 3671/4885
US-20250313547-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 HTT 1235/4885HPGD 4345/4885ALDH1A1 3671/4885
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 HTT 1235/4885HPGD 4345/4885ALDH1A1 3671/4885
US-12441708-B2 Cereblon ligands and bifunctional compounds comprising the same CRBN, CBL, MDM2 HTT 1235/4885HPGD 4345/4885ALDH1A1 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.